Cagrilintide - New Rx? (Obesity Doctor)
A four-minute overview from an obesity medicine doctor of cagrilintide, an amylin analog she says is heading toward approval, and the combination product expected to pair it with semaglutide.
With Dr. Meghan (MD, board certified in Internal Medicine, lifestyle medicine and obesity medicine)
Key moments
Tap a moment to play the video from there.
- 0:00Introduction and who is speakingDr. Meghan introduces herself and her credentials, then sets up cagrilintide as a medication on the horizon.
- 0:39What cagrilintide isShe says it is made by Novo Nordisk, is not a GLP-1 drug, and is a synthetic analog of the pancreatic peptide amylin.
- 1:23Stomach emptying and glucagonShe describes it slowing stomach emptying like GLP-1 drugs and reducing the release of glucagon from the pancreas.
- 2:03Brain, leptin and reward pathwaysShe says it works alongside insulin and leptin and probably acts in the brain on energy balance and reward pathways.
- 2:34Likely release as CagriSemaShe expects cagrilintide to come out blended with semaglutide as CagriSema, noting both are made by Novo Nordisk.
- 3:06Expected weight loss rangeShe calls the preliminary data very promising and places the likely result between Wegovy and Zepbound, pending more research.
- 3:37Wrap-up and viewer requestsShe calls this a heads up on a drug people may hear about soon and asks what viewers want covered next.
What the video says
Dr. Meghan, who describes herself as a physician board certified in internal medicine, lifestyle medicine and obesity medicine, gives a short briefing on cagrilintide. She presents it as a weight medication she expects to be approved in the near to semi-near future, made by Novo Nordisk, and stresses that it is not a GLP-1 drug.
She explains that cagrilintide is a synthetic version of amylin, a peptide released from the pancreas by the same cells that release insulin. According to her, it acts in several ways. It slows stomach emptying, as the GLP-1 drugs do, and it reduces the release of glucagon, which she describes as a peptide that helps the liver release sugar. She adds that it works with insulin and leptin, which she calls key mediators of fullness, and that it probably acts in the brain on energy balance and reward pathways.
The second half looks at how she expects it to reach patients. She says it will most likely be released as a blend with semaglutide, a product she calls CagriSema, because both drugs come from Novo Nordisk. On expected weight loss she describes the preliminary data as very promising and gives a figure beginning around 15 percent total body weight loss. The captions garble the upper end of that range, so the figure should be checked against her linked references. She says the result looks to fall somewhere between Wegovy and Zepbound, and that more data is still to come.
The video is a brief awareness piece rather than a deep review. She does not walk through trial designs, dosing, side effects or safety, and she points viewers to studies listed in the video description. She also spends a short stretch at the start on her own coaching work for people on GLP-1 drugs, and closes by asking viewers what else they would like covered.
On each compound
Cagrilintide0:39
Dr. Meghan describes cagrilintide as a synthetic amylin analog from Novo Nordisk, not a GLP-1. She says it slows stomach emptying, lowers glucagon release, and likely acts on satiety, energy balance and reward pathways.
See how your DNA reads CagrilintideCagriSema2:34
She says the likely release is CagriSema, a blend of cagrilintide and semaglutide. She calls early weight loss data very promising and places it between Wegovy and Zepbound, pending more data.
See how your DNA reads CagriSemaWhat this video doesn’t settle
- It does not give trial designs, dosing, side effects or safety information for cagrilintide or CagriSema.
- The weight loss figure is described as preliminary, and the auto captions garble the upper end of the range.
- Approval timing is only her expectation (near to semi-near future), not an announced date.
Questions this video answers
What is cagrilintide and is it a GLP-1 drug?
Dr. Meghan says cagrilintide is not a GLP-1 medication. She describes it as a synthetic analog of amylin, a peptide released from the same pancreatic cells as insulin.
How does cagrilintide work according to this video?
She says it slows stomach emptying, reduces glucagon release from the pancreas, and works with insulin and leptin on fullness. She adds that it probably acts in the brain on energy balance and reward pathways.
What is CagriSema?
Dr. Meghan says CagriSema is the combination she expects to be released, a blend of cagrilintide and semaglutide. She notes both are made by Novo Nordisk.
How much weight loss does she expect from cagrilintide plus semaglutide?
She describes preliminary data as very promising, with a figure starting around 15 percent total body weight loss. She says it looks to land between Wegovy and Zepbound, and that more data is pending.
Video by Weight Medicine with Dr. Meghan MD on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
